Cited by 209Protein Kinase Regulation and GTPase SignalingSphingolipid Metabolism and SignalingPI3K/AKT/mTOR signaling in cancer

Targeting phospholipase D in cancer, infection and neurodegenerative disorders

Open access
Brown, H. Alex, Thomas, Paul G., Lindsley, Craig W.·2017·Nature Reviews Drug Discovery

Abstract

Lipid second messengers have essential roles in cellular function and contribute to the molecular mechanisms that underlie inflammation, malignant transformation, invasiveness, neurodegenerative disorders, and infectious and other pathophysiological processes. The phospholipase D (PLD) isoenzymes PLD1 and PLD2 are one of the major sources of signal-activated phosphatidic acid (PtdOH) generation downstream of a variety of cell-surface receptors, including G protein-coupled receptors (GPCRs), receptor tyrosine kinases (RTKs) and integrins. Recent advances in the development of isoenzyme-selective PLD inhibitors and in molecular genetics have suggested that PLD isoenzymes in mammalian cells and pathogenic organisms may be valuable targets for the treatment of several human diseases. Isoenzyme-selective inhibitors have revealed complex inter-relationships between PtdOH biosynthetic pathways and the role of PtdOH in pathophysiology. PLD enzymes were once thought to be undruggable owing to the ubiquitous nature of PtdOH in cell signalling and concerns that inhibitors would be too toxic for use in humans. However, recent promising discoveries suggest that small-molecule isoenzyme-selective inhibitors may provide novel compounds for a unique approach to the treatment of cancers, neurodegenerative disorders and other afflictions of the central nervous system, and potentially serve as broad-spectrum antiviral and antimicrobial therapeutics.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrd.2016.252

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • PLD1 is frequently upregulated in various types of cancer including HCC.

    “PLD1 is frequently upregulated in various types of cancer including HCC.[25]”

    From TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis (2021) · cites this paper as [25]

    The 'PLD in cancer signalling pathways' section reports elevated expression of PLD enzymes across several human cancers and discusses PLD1's role in cancer. It does not establish that PLD1 specifically is frequently upregulated, and its list of cancer types does not include HCC. No page number is available in our copy. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

3 of the 118 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Brown, H. A., Thomas, P. G., & Lindsley, C. W.
Affiliations
  • Vanderbilt University (US)
  • St. Jude Children's Research Hospital (US)
Corresponding author
Brown, H. Alex
Venue
Nature Reviews Drug Discovery
Published
2017-02-17
Volume
16
Issue
5
Pages
351-367
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W2588185867
Cited by
209
References
118
Citations by year
2026: 9 · 2025: 14 · 2024: 17 · 2023: 32 · 2022: 27 · 2021: 17 · 2020: 29 · 2019: 28 · 2018: 24 · 2017: 11
FWCI
2.36
Type
journal article
Language
en
Open access
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Voices Against Brain Cancer
  • Vanderbilt University
  • Hartwell Foundation
  • National Institutes of Health (HHSN272201400006C)
  • National Institute of General Medical Sciences (R01GM121629)
  • National Institute of Allergy and Infectious Diseases (HHSN272200800058C, HHSN 272201400006C)
  • Vanderbilt Institute of Chemical Biology, School of Medicine, Vanderbilt University
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
phospholipase D, phospholipase D1, phospholipase D2, phosphatidic acid, lipid second messengers, cancer, neurodegenerative diseases, infection, antiviral agents, antimicrobial agents, G protein-coupled receptors, receptor tyrosine kinase, integrins, signal transduction
MeSH terms
Animals, Enzyme Inhibitors, Humans, Infections, Isoenzymes, Molecular Biology, Neoplasms, Phosphatidic Acids, Phospholipase D, Drug Design, Neurodegenerative Diseases, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review